OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Kalshi is Betting on Trial Results and FDA Decisions Now, What's Next?

FDA Announces 3 Final Guidances to Increase Patient Participation in Oncology Trials

Evis Sala Announces a Landmark Oncology Partnership Between Albania and Italy

SABCS 2026 Male Breast Cancer Advocate Scholarship

RxPONDER Analysis: Ovarian Reserve May Refine Chemotherapy Decisions in HR-Positive Breast Cancer

Herbert Loong: Prospective Open-labelled Phase 2 Pembrolizumab in Acral Lentiginous Melanoma

First Chemotherapy Session: What to Expect

Wafik El-Deiry: Scientific Freedom and Diverse Thinking Drive Better Medicine

Calculators

Khorana Score (Cancer-Associated VTE Risk)

Estimates venous thromboembolism (VTE) risk in ambulatory cancer patients using the validated Khorana score.

Khorana Score Points:

  • Very high-risk site (Stomach, Pancreas): +2
  • High-risk site (Lung, Lymphoma, Gynecologic, Bladder, Testicular): +1
  • Platelets ≥350 ×10⁹/L: +1
  • Hemoglobin <10 g/dL or ESA use: +1
  • WBC >11 ×10⁹/L: +1
  • BMI ≥35 kg/m²: +1

Risk Categories:

  • Low risk: 0 points
  • Intermediate risk: 1-2 points
  • High risk: ≥3 points